Gilles de la Tourette’s syndrome
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Gilles de la Tourette’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Gilles de la Tourette’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gilles de la Tourette’s syndrome: Overview
Tourette syndrome (TS) is a disorder that affects the body's brain and nervous system by causing tics — sudden, repetitive movements or sounds that some people make, seemingly without realizing it. A person with Tourette syndrome has mulitple motor tics and at least one vocal tic. Tics are actually more common in teens than you might think. You may know someone who has either a motor tic (sudden, uncontrollable movements like exaggerated blinking of the eyes) or a vocal tic (sounds such as throat clearing, grunting, or humming). Tourette syndrome is a genetic disorder, which means it's the result of a change in genes that's either inherited (passed on from parent to child) or happens during development in the womb. As with other genetic disorders, someone may have a tendency to develop TS. But that doesn't mean the person will definitely get it.
'Gilles de la Tourette’s syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gilles de la Tourette’s syndrome pipeline landscape is provided which includes the disease overview and Gilles de la Tourette’s syndrome treatment guidelines. The assessment part of the report embraces, in depth Gilles de la Tourette’s syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gilles de la Tourette’s syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gilles de la Tourette’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gilles de la Tourette’s syndrome Emerging Drugs
Further product details are provided in the report
Gilles de la Tourette’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Gilles de la Tourette’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Gilles de la Tourette’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gilles de la Tourette’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gilles de la Tourette’s syndrome drugs.
Gilles de la Tourette’s syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Gilles de la Tourette’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Gilles de la Tourette’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gilles de la Tourette’s syndrome: Overview
Tourette syndrome (TS) is a disorder that affects the body's brain and nervous system by causing tics — sudden, repetitive movements or sounds that some people make, seemingly without realizing it. A person with Tourette syndrome has mulitple motor tics and at least one vocal tic. Tics are actually more common in teens than you might think. You may know someone who has either a motor tic (sudden, uncontrollable movements like exaggerated blinking of the eyes) or a vocal tic (sounds such as throat clearing, grunting, or humming). Tourette syndrome is a genetic disorder, which means it's the result of a change in genes that's either inherited (passed on from parent to child) or happens during development in the womb. As with other genetic disorders, someone may have a tendency to develop TS. But that doesn't mean the person will definitely get it.
'Gilles de la Tourette’s syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gilles de la Tourette’s syndrome pipeline landscape is provided which includes the disease overview and Gilles de la Tourette’s syndrome treatment guidelines. The assessment part of the report embraces, in depth Gilles de la Tourette’s syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gilles de la Tourette’s syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gilles de la Tourette’s syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Gilles de la Tourette’s syndrome.
This segment of the Gilles de la Tourette’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gilles de la Tourette’s syndrome Emerging Drugs
- Ecopipam: Emalex Biosciences
- THX-110: Therapix Biosciences
Further product details are provided in the report
Gilles de la Tourette’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Gilles de la Tourette’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gilles de la Tourette’s syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gilles de la Tourette’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gilles de la Tourette’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gilles de la Tourette’s syndrome drugs.
Gilles de la Tourette’s syndrome Report Insights
- Gilles de la Tourette’s syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gilles de la Tourette’s syndrome drugs?
- How many Gilles de la Tourette’s syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gilles de la Tourette’s syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gilles de la Tourette’s syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gilles de la Tourette’s syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Emalex Biosciences
- Therapix Biosciences
- Catalyst Pharmaceuticals
- KemPharm
- Teva Pharmaceutical
- Neurocrine Biosciences
- Asarina Pharma
- SOM Biotech
- Ecopipam
- THX-110
- CPP 115
- Gilles de la Tourette's syndrome prodrug therapeutic
- Deutetrabenazine
- NBI-98854
- Sepranolone
- SOM3355
Introduction
Executive Summary
Gilles de la Tourette’s syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gilles de la Tourette’s syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gilles de la Tourette’s syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gilles de la Tourette’s syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Deutetrabenazine: Teva Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Ecopipam: Emalex Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Gilles de la Tourette’s syndrome Key Companies
Gilles de la Tourette’s syndrome Key Products
Gilles de la Tourette’s syndrome- Unmet Needs
Gilles de la Tourette’s syndrome- Market Drivers and Barriers
Gilles de la Tourette’s syndrome- Future Perspectives and Conclusion
Gilles de la Tourette’s syndrome Analyst Views
Gilles de la Tourette’s syndrome Key Companies
Appendix
Executive Summary
Gilles de la Tourette’s syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gilles de la Tourette’s syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gilles de la Tourette’s syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gilles de la Tourette’s syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Deutetrabenazine: Teva Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Ecopipam: Emalex Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Gilles de la Tourette’s syndrome Key Companies
Gilles de la Tourette’s syndrome Key Products
Gilles de la Tourette’s syndrome- Unmet Needs
Gilles de la Tourette’s syndrome- Market Drivers and Barriers
Gilles de la Tourette’s syndrome- Future Perspectives and Conclusion
Gilles de la Tourette’s syndrome Analyst Views
Gilles de la Tourette’s syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Gilles de la Tourette’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gilles de la Tourette’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gilles de la Tourette’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gilles de la Tourette’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products